PMC:7205724 / 17405-19470
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 599 | 90-95 | Species | denotes | human | Tax:9606 |
| 613 | 179-184 | Species | denotes | human | Tax:9606 |
| 614 | 369-383 | Species | denotes | Parvovirus B19 | Tax:10798 |
| 615 | 430-451 | Species | denotes | Clostridium difficile | Tax:1496 |
| 616 | 464-483 | Species | denotes | Mycobacterium avium | Tax:1764 |
| 617 | 485-511 | Species | denotes | Mycobacterium tuberculosis | Tax:1773 |
| 618 | 240-260 | Disease | denotes | autoimmune disorders | MESH:D001327 |
| 619 | 264-293 | Disease | denotes | primary antibody deficiencies | MESH:D000081207 |
| 620 | 361-367 | Disease | denotes | sepsis | MESH:D018805 |
| 621 | 384-393 | Disease | denotes | infection | MESH:D007239 |
| 622 | 405-423 | Disease | denotes | virus encephalitis | MESH:D004660 |
| 623 | 452-462 | Disease | denotes | infections | MESH:D007239 |
| 624 | 517-536 | Disease | denotes | Nocardia infections | MESH:D009617 |
| 625 | 552-562 | Disease | denotes | infections | MESH:D007239 |
| 633 | 663-672 | Species | denotes | 2019-nCoV | Tax:2697049 |
| 634 | 897-905 | Species | denotes | patients | Tax:9606 |
| 635 | 609-617 | Species | denotes | patients | Tax:9606 |
| 636 | 702-711 | Disease | denotes | infection | MESH:D007239 |
| 637 | 911-918 | Disease | denotes | COVID19 | MESH:C000657245 |
| 638 | 1037-1044 | Disease | denotes | COVID19 | MESH:C000657245 |
| 639 | 1128-1136 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 642 | 1199-1207 | Species | denotes | patients | Tax:9606 |
| 643 | 1213-1221 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 651 | 1250-1258 | Species | denotes | patients | Tax:9606 |
| 652 | 1628-1636 | Species | denotes | patients | Tax:9606 |
| 653 | 1362-1366 | Chemical | denotes | FIO2 | |
| 654 | 1377-1383 | Chemical | denotes | oxygen | MESH:D010100 |
| 655 | 1464-1482 | Chemical | denotes | methylprednisolone | MESH:D008775 |
| 656 | 1570-1588 | Chemical | denotes | methylprednisolone | MESH:D008775 |
| 657 | 1264-1272 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 661 | 1812-1819 | Species | denotes | patient | Tax:9606 |
| 662 | 1869-1878 | Species | denotes | 2019-nCoV | Tax:2697049 |
| 663 | 2013-2021 | Species | denotes | patients | Tax:9606 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T134 | 17-32 | Body_part | denotes | immunoglobulins | http://purl.org/sig/ont/fma/fma62871 |
| T135 | 272-280 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
| T136 | 425-428 | Body_part | denotes | HIV | http://purl.org/sig/ont/fma/fma278683 |
| T137 | 736-741 | Body_part | denotes | serum | http://purl.org/sig/ont/fma/fma63083 |
| T138 | 818-821 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
| T139 | 826-829 | Body_part | denotes | IgM | http://purl.org/sig/ont/fma/fma62873 |
| T140 | 961-975 | Body_part | denotes | immunoglobulin | http://purl.org/sig/ont/fma/fma62871 |
| T141 | 1326-1336 | Body_part | denotes | lymphocyte | http://purl.org/sig/ont/fma/fma62863 |
| T142 | 1497-1511 | Body_part | denotes | immunoglobulin | http://purl.org/sig/ont/fma/fma62871 |
| T143 | 1601-1615 | Body_part | denotes | immunoglobulin | http://purl.org/sig/ont/fma/fma62871 |
| T144 | 1862-1865 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
| T145 | 1956-1959 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
| T146 | 1964-1967 | Body_part | denotes | IgM | http://purl.org/sig/ont/fma/fma62873 |
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T20 | 736-741 | Body_part | denotes | serum | http://purl.obolibrary.org/obo/UBERON_0001977 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T123 | 240-260 | Disease | denotes | autoimmune disorders | http://purl.obolibrary.org/obo/MONDO_0007179 |
| T124 | 264-293 | Disease | denotes | primary antibody deficiencies | http://purl.obolibrary.org/obo/MONDO_0015517 |
| T125 | 384-393 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T126 | 405-423 | Disease | denotes | virus encephalitis | http://purl.obolibrary.org/obo/MONDO_0006009 |
| T127 | 411-423 | Disease | denotes | encephalitis | http://purl.obolibrary.org/obo/MONDO_0019956 |
| T128 | 430-462 | Disease | denotes | Clostridium difficile infections | http://purl.obolibrary.org/obo/MONDO_0000705 |
| T129 | 499-511 | Disease | denotes | tuberculosis | http://purl.obolibrary.org/obo/MONDO_0018076 |
| T130 | 517-536 | Disease | denotes | Nocardia infections | http://purl.obolibrary.org/obo/MONDO_0017776 |
| T131 | 552-565 | Disease | denotes | infections in | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T132 | 566-597 | Disease | denotes | primary antibodies deficiencies | http://purl.obolibrary.org/obo/MONDO_0015517 |
| T133 | 702-711 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T134 | 911-918 | Disease | denotes | COVID19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T135 | 1037-1044 | Disease | denotes | COVID19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T136 | 1128-1136 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T137 | 1213-1221 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T138 | 1264-1272 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T217 | 74-75 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T218 | 90-95 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
| T219 | 166-167 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T220 | 179-184 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
| T221 | 306-309 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T222 | 380-383 | http://purl.obolibrary.org/obo/CLO_0001798 | denotes | B19 |
| T223 | 405-410 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T224 | 649-651 | http://purl.obolibrary.org/obo/CLO_0008192 | denotes | NP |
| T225 | 719-721 | http://purl.obolibrary.org/obo/CLO_0050507 | denotes | 22 |
| T226 | 849-851 | http://purl.obolibrary.org/obo/CLO_0008192 | denotes | NP |
| T227 | 855-857 | http://purl.obolibrary.org/obo/CLO_0001527 | denotes | 94 |
| T228 | 887-889 | http://purl.obolibrary.org/obo/CLO_0001527 | denotes | 94 |
| T229 | 1246-1249 | http://purl.obolibrary.org/obo/CLO_0050884 | denotes | ten |
| T230 | 1421-1422 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T156 | 649-651 | Chemical | denotes | NP | http://purl.obolibrary.org/obo/CHEBI_50803|http://purl.obolibrary.org/obo/CHEBI_53793|http://purl.obolibrary.org/obo/CHEBI_73425 |
| T159 | 849-851 | Chemical | denotes | NP | http://purl.obolibrary.org/obo/CHEBI_50803|http://purl.obolibrary.org/obo/CHEBI_53793|http://purl.obolibrary.org/obo/CHEBI_73425 |
| T162 | 1377-1383 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
| T163 | 1448-1462 | Chemical | denotes | corticosteroid | http://purl.obolibrary.org/obo/CHEBI_50858 |
| T164 | 1464-1482 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
| T165 | 1570-1588 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
LitCovid-sample-MedDRA
| Id | Subject | Object | Predicate | Lexical cue | meddra_id |
|---|---|---|---|---|---|
| T12 | 17-32 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | immunoglobulins | http://purl.bioontology.org/ontology/MEDDRA/10021496 |
| T13 | 961-975 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | immunoglobulin | http://purl.bioontology.org/ontology/MEDDRA/10021496 |
| T14 | 1326-1356 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | lymphocyte count and decreased | http://purl.bioontology.org/ontology/MEDDRA/10025256 |
| T15 | 1357-1372 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | PaO2/FIO2 ratio | http://purl.bioontology.org/ontology/MEDDRA/10077710 |
| T16 | 1377-1394 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | oxygen saturation | http://purl.bioontology.org/ontology/MEDDRA/10033316 |
| T17 | 1497-1511 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | immunoglobulin | http://purl.bioontology.org/ontology/MEDDRA/10021496 |
| T18 | 1601-1615 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | immunoglobulin | http://purl.bioontology.org/ontology/MEDDRA/10021496 |
LitCovid-sample-PD-IDO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T70 | 185-193 | http://purl.obolibrary.org/obo/OGMS_0000031 | denotes | diseases |
| T71 | 251-260 | http://purl.obolibrary.org/obo/OGMS_0000045 | denotes | disorders |
| T72 | 361-367 | http://purl.obolibrary.org/obo/IDO_0000636 | denotes | sepsis |
| T73 | 384-393 | http://purl.obolibrary.org/obo/IDO_0000586 | denotes | infection |
| T74 | 405-410 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T75 | 452-462 | http://purl.obolibrary.org/obo/IDO_0000586 | denotes | infections |
| T76 | 526-536 | http://purl.obolibrary.org/obo/IDO_0000586 | denotes | infections |
| T77 | 552-565 | http://purl.obolibrary.org/obo/IDO_0000586 | denotes | infections in |
| T78 | 702-711 | http://purl.obolibrary.org/obo/IDO_0000586 | denotes | infection |
| T79 | 782-789 | http://purl.obolibrary.org/obo/OGMS_0000020 | denotes | symptom |
| T80 | 1300-1308 | http://purl.obolibrary.org/obo/OGMS_0000020 | denotes | symptoms |
| T81 | 1740-1747 | http://purl.obolibrary.org/obo/OGMS_0000031 | denotes | disease |
LitCovid-sample-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T103 | 1377-1383 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
| T104 | 1448-1462 | Chemical | denotes | corticosteroid | http://purl.obolibrary.org/obo/CHEBI_50858 |
| T105 | 1464-1482 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
| T106 | 1570-1588 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
| T107 | 1862-1865 | Chemical | denotes | RNA | http://purl.obolibrary.org/obo/CHEBI_33697 |
LitCovid-sample-PD-NCBITaxon
| Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
|---|---|---|---|---|---|
| T165 | 90-95 | Species | denotes | human | NCBItxid:9606 |
| T166 | 179-184 | Species | denotes | human | NCBItxid:9606 |
| T167 | 361-367 | Species | denotes | sepsis | NCBItxid:137507 |
| T168 | 369-383 | Species | denotes | Parvovirus B19 | NCBItxid:10798 |
| T169 | 395-410 | Species | denotes | West Nile virus | NCBItxid:11082 |
| T170 | 425-428 | Species | denotes | HIV | NCBItxid:57667|NCBItxid:35274|NCBItxid:12721|NCBItxid:11709|NCBItxid:11676 |
| T175 | 430-451 | Species | denotes | Clostridium difficile | NCBItxid:1496 |
| T176 | 464-483 | Species | denotes | Mycobacterium avium | NCBItxid:1764 |
| T177 | 485-511 | Species | denotes | Mycobacterium tuberculosis | NCBItxid:1773 |
| T178 | 517-525 | Species | denotes | Nocardia | NCBItxid:1817 |
| T179 | 663-672 | Species | denotes | 2019-nCoV | NCBItxid:2697049 |
| T180 | 911-918 | Species | denotes | COVID19 | NCBItxid:2697049 |
| T181 | 1037-1044 | Species | denotes | COVID19 | NCBItxid:2697049 |
| T182 | 1128-1136 | Species | denotes | COVID-19 | NCBItxid:2697049 |
| T183 | 1213-1221 | Species | denotes | COVID-19 | NCBItxid:2697049 |
| T184 | 1264-1272 | Species | denotes | COVID-19 | NCBItxid:2697049 |
| T185 | 1869-1878 | Species | denotes | 2019-nCoV | NCBItxid:2697049 |
LitCovid-sample-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T141 | 0-39 | Sentence | denotes | 4.2 Intravenous immunoglobulins (IVIG) |
| T142 | 41-106 | Sentence | denotes | 4.2.1 Hypothesis: IVIG contains a large pool of human antibodies |
| T143 | 107-294 | Sentence | denotes | IVIG is an immunomodulatory treatment currently useful for a variety of human diseases that share an idiopathic origin, ranging from autoimmune disorders to primary antibody deficiencies. |
| T144 | 295-603 | Sentence | denotes | Also, IVIG has shown promising results in case of severe (such as sepsis, Parvovirus B19 infection, West Nile virus encephalitis, HIV, Clostridium difficile infections, Mycobacterium avium, Mycobacterium tuberculosis, and Nocardia infections) and recurrent infections in primary antibodies deficiencies [21]. |
| T145 | 604-723 | Sentence | denotes | Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22]. |
| T146 | 724-919 | Sentence | denotes | Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19. |
| T147 | 920-1045 | Sentence | denotes | Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19. |
| T148 | 1046-1137 | Sentence | denotes | It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19. |
| T149 | 1139-1221 | Sentence | denotes | 4.2.2 Rationale: IVIG might help to improve the outcome of patients with COVID-19 |
| T150 | 1222-1521 | Sentence | denotes | The study [23] included ten patients with COVID-19 who demonstrated worsening symptoms, e.g., decreased lymphocyte count and decreased PaO2/FIO2 ratio and oxygen saturation, following treatment with a short-term moderate-dose corticosteroid (methylprednisolone 80 mg/d) plus immunoglobulin (10 g/d). |
| T151 | 1522-1701 | Sentence | denotes | After switching to the double dose of 1600 mg/d methylprednisolone plus 20 g/d immunoglobulin, all of the patients improved in the clinical, laboratory, and paraclinical outcomes. |
| T152 | 1702-1833 | Sentence | denotes | Passive immunization protects against disease, and so it should be administered as early as possible when the patient is diagnosed. |
| T153 | 1834-2065 | Sentence | denotes | Studies show that the viral RNA of 2019-nCoV reaches its peak during the first week and then gradually decreases and that IgG and IgM begin to rise from the 10th day so that most patients have anti-viral antibodies by the 14th day. |
LitCovid-sample-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T20 | 736-741 | Body_part | denotes | serum | http://purl.obolibrary.org/obo/UBERON_0001977 |
LitCovid-sample-Pubtator
| Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
|---|---|---|---|---|---|
| 599 | 90-95 | Species | denotes | human | Tax:9606 |
| 613 | 179-184 | Species | denotes | human | Tax:9606 |
| 618 | 240-260 | Disease | denotes | autoimmune disorders | MESH:D001327 |
| 619 | 264-293 | Disease | denotes | primary antibody deficiencies | MESH:D000081207 |
| 620 | 361-367 | Disease | denotes | sepsis | MESH:D018805 |
| 614 | 369-383 | Species | denotes | Parvovirus B19 | Tax:10798 |
| 621 | 384-393 | Disease | denotes | infection | MESH:D007239 |
| 622 | 405-423 | Disease | denotes | virus encephalitis | MESH:D004660 |
| 615 | 430-451 | Species | denotes | Clostridium difficile | Tax:1496 |
| 623 | 452-462 | Disease | denotes | infections | MESH:D007239 |
| 616 | 464-483 | Species | denotes | Mycobacterium avium | Tax:1764 |
| 617 | 485-511 | Species | denotes | Mycobacterium tuberculosis | Tax:1773 |
| 624 | 517-536 | Disease | denotes | Nocardia infections | MESH:D009617 |
| 625 | 552-562 | Disease | denotes | infections | MESH:D007239 |
| 635 | 609-617 | Species | denotes | patients | Tax:9606 |
| 633 | 663-672 | Species | denotes | 2019-nCoV | Tax:2697049 |
| 636 | 702-711 | Disease | denotes | infection | MESH:D007239 |
| 634 | 897-905 | Species | denotes | patients | Tax:9606 |
| 637 | 911-918 | Disease | denotes | COVID19 | MESH:C000657245 |
| 638 | 1037-1044 | Disease | denotes | COVID19 | MESH:C000657245 |
| 639 | 1128-1136 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 642 | 1199-1207 | Species | denotes | patients | Tax:9606 |
| 643 | 1213-1221 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 651 | 1250-1258 | Species | denotes | patients | Tax:9606 |
| 657 | 1264-1272 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 653 | 1362-1366 | Chemical | denotes | FIO2 | |
| 654 | 1377-1383 | Chemical | denotes | oxygen | MESH:D010100 |
| 655 | 1464-1482 | Chemical | denotes | methylprednisolone | MESH:D008775 |
| 656 | 1570-1588 | Chemical | denotes | methylprednisolone | MESH:D008775 |
| 652 | 1628-1636 | Species | denotes | patients | Tax:9606 |
| 661 | 1812-1819 | Species | denotes | patient | Tax:9606 |
| 662 | 1869-1878 | Species | denotes | 2019-nCoV | Tax:2697049 |
| 663 | 2013-2021 | Species | denotes | patients | Tax:9606 |
LitCovid-sample-UniProt
| Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
|---|---|---|---|---|---|
| T1970 | 380-383 | Protein | denotes | B19 | https://www.uniprot.org/uniprot/P57058 |
| T1971 | 656-659 | Protein | denotes | RBD | https://www.uniprot.org/uniprot/Q63492|https://www.uniprot.org/uniprot/Q63491|https://www.uniprot.org/uniprot/Q62815|https://www.uniprot.org/uniprot/Q62691|https://www.uniprot.org/uniprot/Q01542|https://www.uniprot.org/uniprot/P27732|https://www.uniprot.org/uniprot/O09024|https://www.uniprot.org/uniprot/O09023|https://www.uniprot.org/uniprot/O09022 |
| T1980 | 871-874 | Protein | denotes | RBD | https://www.uniprot.org/uniprot/Q63492|https://www.uniprot.org/uniprot/Q63491|https://www.uniprot.org/uniprot/Q62815|https://www.uniprot.org/uniprot/Q62691|https://www.uniprot.org/uniprot/Q01542|https://www.uniprot.org/uniprot/P27732|https://www.uniprot.org/uniprot/O09024|https://www.uniprot.org/uniprot/O09023|https://www.uniprot.org/uniprot/O09022 |
LitCovid-sample-Enju
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T55819 | 0-3 | CD | denotes | 4.2 |
| T56180 | 5-16 | JJ | denotes | Intravenous |
| T2182 | 17-32 | NNS | denotes | immunoglobulins |
| T41175 | 33-34 | -LRB- | denotes | ( |
| T97867 | 34-38 | NN | denotes | IVIG |
| T16816 | 38-39 | -RRB- | denotes | ) |
| T56020 | 41-46 | CD | denotes | 4.2.1 |
| T95212 | 48-58 | NN | denotes | Hypothesis |
| T84611 | 58-59 | -COLON- | denotes | : |
| T95417 | 60-64 | NN | denotes | IVIG |
| T50853 | 65-73 | VBZ | denotes | contains |
| T65863 | 74-75 | DT | denotes | a |
| T68527 | 76-81 | JJ | denotes | large |
| T83960 | 82-86 | NN | denotes | pool |
| T57480 | 87-89 | IN | denotes | of |
| T98962 | 90-95 | JJ | denotes | human |
| T50450 | 96-106 | NNS | denotes | antibodies |
| T12037 | 107-111 | NN | denotes | IVIG |
| T52317 | 112-114 | VBZ | denotes | is |
| T83276 | 115-117 | DT | denotes | an |
| T47689 | 118-134 | JJ | denotes | immunomodulatory |
| T32201 | 135-144 | NN | denotes | treatment |
| T26744 | 145-154 | RB | denotes | currently |
| T6595 | 155-161 | JJ | denotes | useful |
| T61951 | 162-165 | IN | denotes | for |
| T78252 | 166-167 | DT | denotes | a |
| T96672 | 168-175 | NN | denotes | variety |
| T75647 | 176-178 | IN | denotes | of |
| T64366 | 179-184 | JJ | denotes | human |
| T37666 | 185-193 | NNS | denotes | diseases |
| T30663 | 194-198 | WDT | denotes | that |
| T71611 | 199-204 | VBP | denotes | share |
| T4369 | 205-207 | DT | denotes | an |
| T95969 | 208-218 | JJ | denotes | idiopathic |
| T35011 | 219-225 | NN | denotes | origin |
| T94518 | 225-226 | -COMMA- | denotes | , |
| T34533 | 227-234 | VBG | denotes | ranging |
| T57537 | 235-239 | IN | denotes | from |
| T47481 | 240-250 | JJ | denotes | autoimmune |
| T10634 | 251-260 | NNS | denotes | disorders |
| T96539 | 261-263 | TO | denotes | to |
| T18270 | 264-271 | JJ | denotes | primary |
| T92790 | 272-280 | NN | denotes | antibody |
| T91348 | 281-293 | NNS | denotes | deficiencies |
| T23275 | 295-299 | RB | denotes | Also |
| T97483 | 299-300 | -COMMA- | denotes | , |
| T12179 | 301-305 | NNP | denotes | IVIG |
| T44219 | 306-309 | VBZ | denotes | has |
| T10629 | 310-315 | VBN | denotes | shown |
| T45168 | 316-325 | JJ | denotes | promising |
| T67208 | 326-333 | NNS | denotes | results |
| T77083 | 334-336 | IN | denotes | in |
| T72909 | 337-341 | NN | denotes | case |
| T84121 | 342-344 | IN | denotes | of |
| T92712 | 345-351 | JJ | denotes | severe |
| T79863 | 352-353 | -LRB- | denotes | ( |
| T66824 | 353-357 | JJ | denotes | such |
| T43956 | 358-360 | IN | denotes | as |
| T9832 | 361-367 | NN | denotes | sepsis |
| T13628 | 367-368 | -COMMA- | denotes | , |
| T62406 | 369-379 | NN | denotes | Parvovirus |
| T99835 | 380-383 | NN | denotes | B19 |
| T14835 | 384-393 | NN | denotes | infection |
| T15497 | 393-394 | -COMMA- | denotes | , |
| T90831 | 395-399 | NNP | denotes | West |
| T76795 | 400-404 | NNP | denotes | Nile |
| T72325 | 405-410 | NN | denotes | virus |
| T62294 | 411-423 | NN | denotes | encephalitis |
| T79163 | 423-424 | -COMMA- | denotes | , |
| T42313 | 425-428 | NN | denotes | HIV |
| T73958 | 428-429 | -COMMA- | denotes | , |
| T29310 | 430-441 | NNP | denotes | Clostridium |
| T49447 | 442-451 | JJ | denotes | difficile |
| T8038 | 452-462 | NNS | denotes | infections |
| T10219 | 462-463 | -COMMA- | denotes | , |
| T3443 | 464-477 | NN | denotes | Mycobacterium |
| T55185 | 478-483 | NN | denotes | avium |
| T2677 | 483-484 | -COMMA- | denotes | , |
| T67405 | 485-498 | NN | denotes | Mycobacterium |
| T65630 | 499-511 | NN | denotes | tuberculosis |
| T60726 | 511-512 | -COMMA- | denotes | , |
| T52785 | 513-516 | CC | denotes | and |
| T44446 | 517-525 | NNP | denotes | Nocardia |
| T90848 | 526-536 | NNS | denotes | infections |
| T80386 | 536-537 | -RRB- | denotes | ) |
| T6178 | 538-541 | CC | denotes | and |
| T68317 | 542-551 | JJ | denotes | recurrent |
| T17705 | 552-562 | NNS | denotes | infections |
| T68999 | 563-565 | IN | denotes | in |
| T18422 | 566-573 | JJ | denotes | primary |
| T52471 | 574-584 | NNS | denotes | antibodies |
| T62247 | 585-597 | NNS | denotes | deficiencies |
| T55724 | 598-599 | -LRB- | denotes | [ |
| T27007 | 599-601 | CD | denotes | 21 |
| T97422 | 601-602 | -RRB- | denotes | ] |
| T8813 | 604-608 | JJS | denotes | Most |
| T48684 | 609-617 | NNS | denotes | patients |
| T37814 | 618-625 | VBP | denotes | develop |
| T41895 | 626-636 | NNS | denotes | antibodies |
| T32237 | 637-644 | IN | denotes | against |
| T55833 | 645-648 | DT | denotes | the |
| T23466 | 649-651 | NN | denotes | NP |
| T51386 | 652-655 | CC | denotes | and |
| T97267 | 656-659 | NN | denotes | RBD |
| T48238 | 660-662 | IN | denotes | of |
| T17626 | 663-672 | NN | denotes | 2019-nCoV |
| T87676 | 673-679 | IN | denotes | during |
| T56543 | 680-683 | DT | denotes | the |
| T74019 | 684-690 | JJ | denotes | second |
| T36179 | 691-695 | NN | denotes | week |
| T61939 | 696-701 | IN | denotes | after |
| T53819 | 702-711 | NN | denotes | infection |
| T47949 | 712-717 | NN | denotes | onset |
| T10621 | 718-719 | -LRB- | denotes | [ |
| T31327 | 719-721 | CD | denotes | 22 |
| T53799 | 721-722 | -RRB- | denotes | ] |
| T76985 | 724-732 | NN | denotes | Analysis |
| T6758 | 733-735 | IN | denotes | of |
| T88720 | 736-741 | NN | denotes | serum |
| T73739 | 742-749 | NNS | denotes | samples |
| T20072 | 750-759 | VBD | denotes | collected |
| T30704 | 760-762 | CD | denotes | 14 |
| T66398 | 763-765 | CC | denotes | or |
| T43796 | 766-770 | JJR | denotes | more |
| T64515 | 771-775 | NNS | denotes | days |
| T88119 | 776-781 | IN | denotes | after |
| T33297 | 782-789 | NN | denotes | symptom |
| T78997 | 790-795 | NN | denotes | onset |
| T69102 | 796-804 | VBD | denotes | revealed |
| T51393 | 805-814 | NN | denotes | detection |
| T49412 | 815-817 | IN | denotes | of |
| T86080 | 818-821 | NN | denotes | IgG |
| T42365 | 822-825 | CC | denotes | and |
| T24248 | 826-829 | NN | denotes | IgM |
| T84785 | 830-840 | NNS | denotes | antibodies |
| T33598 | 841-848 | IN | denotes | against |
| T65176 | 849-851 | NN | denotes | NP |
| T29543 | 852-854 | IN | denotes | in |
| T67075 | 855-857 | CD | denotes | 94 |
| T4274 | 857-858 | NN | denotes | % |
| T73088 | 859-862 | CC | denotes | and |
| T74097 | 863-865 | CD | denotes | 88 |
| T71868 | 865-866 | NN | denotes | % |
| T54079 | 867-870 | CC | denotes | and |
| T73098 | 871-874 | NN | denotes | RBD |
| T69539 | 875-877 | IN | denotes | in |
| T87988 | 878-881 | CD | denotes | 100 |
| T78691 | 881-882 | NN | denotes | % |
| T18580 | 883-886 | CC | denotes | and |
| T46489 | 887-889 | CD | denotes | 94 |
| T64615 | 889-890 | NN | denotes | % |
| T60810 | 891-896 | IN | denotes | among |
| T38563 | 897-905 | NNS | denotes | patients |
| T93829 | 906-910 | IN | denotes | with |
| T24980 | 911-918 | NN | denotes | COVID19 |
| T89545 | 920-927 | NNS | denotes | Studies |
| T44838 | 928-940 | RB | denotes | consistently |
| T54246 | 941-945 | VBP | denotes | show |
| T20581 | 946-950 | IN | denotes | that |
| T54967 | 951-960 | VBN | denotes | increased |
| T27422 | 961-975 | NN | denotes | immunoglobulin |
| T48431 | 976-982 | NNS | denotes | levels |
| T7060 | 983-992 | VBP | denotes | accompany |
| T92743 | 993-996 | DT | denotes | the |
| T24866 | 997-1007 | NN | denotes | transition |
| T9522 | 1008-1012 | IN | denotes | from |
| T69120 | 1013-1018 | JJ | denotes | early |
| T81312 | 1019-1021 | TO | denotes | to |
| T7048 | 1022-1026 | JJ | denotes | late |
| T25388 | 1027-1033 | NN | denotes | course |
| T44741 | 1034-1036 | IN | denotes | of |
| T20679 | 1037-1044 | NN | denotes | COVID19 |
| T6735 | 1046-1048 | PRP | denotes | It |
| T32751 | 1049-1054 | VBZ | denotes | poses |
| T41840 | 1055-1058 | DT | denotes | the |
| T21434 | 1059-1070 | NN | denotes | possibility |
| T75450 | 1071-1075 | IN | denotes | that |
| T55251 | 1076-1080 | NN | denotes | IVIG |
| T48129 | 1081-1088 | NN | denotes | therapy |
| T90120 | 1089-1094 | MD | denotes | might |
| T91321 | 1095-1099 | VB | denotes | help |
| T89890 | 1100-1102 | TO | denotes | to |
| T64443 | 1103-1113 | VB | denotes | accelerate |
| T5150 | 1114-1122 | NN | denotes | recovery |
| T43666 | 1123-1127 | IN | denotes | from |
| T85289 | 1128-1136 | NN | denotes | COVID-19 |
| T72940 | 1139-1144 | CD | denotes | 4.2.2 |
| T31699 | 1146-1155 | NNP | denotes | Rationale |
| T6254 | 1155-1156 | -COLON- | denotes | : |
| T80516 | 1157-1161 | NN | denotes | IVIG |
| T69063 | 1162-1167 | MD | denotes | might |
| T22631 | 1168-1172 | VB | denotes | help |
| T88012 | 1173-1175 | TO | denotes | to |
| T98862 | 1176-1183 | VB | denotes | improve |
| T98671 | 1184-1187 | DT | denotes | the |
| T20348 | 1188-1195 | NN | denotes | outcome |
| T65200 | 1196-1198 | IN | denotes | of |
| T90061 | 1199-1207 | NNS | denotes | patients |
| T66297 | 1208-1212 | IN | denotes | with |
| T53417 | 1213-1221 | NN | denotes | COVID-19 |
| T18993 | 1222-1225 | DT | denotes | The |
| T21718 | 1226-1231 | NN | denotes | study |
| T64168 | 1232-1233 | -LRB- | denotes | [ |
| T66430 | 1233-1235 | CD | denotes | 23 |
| T95152 | 1235-1236 | -RRB- | denotes | ] |
| T31198 | 1237-1245 | VBD | denotes | included |
| T55004 | 1246-1249 | CD | denotes | ten |
| T65830 | 1250-1258 | NNS | denotes | patients |
| T56952 | 1259-1263 | IN | denotes | with |
| T98815 | 1264-1272 | NN | denotes | COVID-19 |
| T69048 | 1273-1276 | WP | denotes | who |
| T75376 | 1277-1289 | VBD | denotes | demonstrated |
| T59786 | 1290-1299 | VBG | denotes | worsening |
| T24326 | 1300-1308 | NNS | denotes | symptoms |
| T13700 | 1308-1309 | -COMMA- | denotes | , |
| T79561 | 1310-1314 | FW | denotes | e.g. |
| T83448 | 1314-1315 | -COMMA- | denotes | , |
| T77014 | 1316-1325 | VBD | denotes | decreased |
| T40148 | 1326-1336 | NN | denotes | lymphocyte |
| T31095 | 1337-1342 | NN | denotes | count |
| T13833 | 1343-1346 | CC | denotes | and |
| T80531 | 1347-1356 | VBD | denotes | decreased |
| T26060 | 1357-1366 | NN | denotes | PaO2/FIO2 |
| T3471 | 1367-1372 | NN | denotes | ratio |
| T11859 | 1373-1376 | CC | denotes | and |
| T6067 | 1377-1383 | NN | denotes | oxygen |
| T65980 | 1384-1394 | NN | denotes | saturation |
| T58632 | 1394-1395 | -COMMA- | denotes | , |
| T52543 | 1396-1405 | VBG | denotes | following |
| T84435 | 1406-1415 | NN | denotes | treatment |
| T44273 | 1416-1420 | IN | denotes | with |
| T99668 | 1421-1422 | DT | denotes | a |
| T65524 | 1423-1433 | JJ | denotes | short-term |
| T66169 | 1434-1447 | JJ | denotes | moderate-dose |
| T25963 | 1448-1462 | NN | denotes | corticosteroid |
| T54040 | 1463-1464 | -LRB- | denotes | ( |
| T15835 | 1464-1482 | NN | denotes | methylprednisolone |
| T75851 | 1483-1490 | NN | denotes | 80 mg/d |
| T55858 | 1490-1491 | -RRB- | denotes | ) |
| T6426 | 1492-1496 | CC | denotes | plus |
| T60445 | 1497-1511 | NN | denotes | immunoglobulin |
| T91733 | 1512-1513 | -LRB- | denotes | ( |
| T10263 | 1513-1519 | CD | denotes | 10 g/d |
| T89099 | 1519-1520 | -RRB- | denotes | ) |
| T32422 | 1522-1527 | IN | denotes | After |
| T38661 | 1528-1537 | VBG | denotes | switching |
| T47400 | 1538-1540 | TO | denotes | to |
| T27854 | 1541-1544 | DT | denotes | the |
| T88178 | 1545-1551 | JJ | denotes | double |
| T22917 | 1552-1556 | NN | denotes | dose |
| T27562 | 1557-1559 | IN | denotes | of |
| T69861 | 1560-1569 | NN | denotes | 1600 mg/d |
| T26688 | 1570-1588 | NN | denotes | methylprednisolone |
| T91618 | 1589-1593 | CC | denotes | plus |
| T63033 | 1594-1600 | NN | denotes | 20 g/d |
| T82872 | 1601-1615 | NN | denotes | immunoglobulin |
| T48110 | 1615-1616 | -COMMA- | denotes | , |
| T64285 | 1617-1620 | DT | denotes | all |
| T67888 | 1621-1623 | IN | denotes | of |
| T16788 | 1624-1627 | DT | denotes | the |
| T67776 | 1628-1636 | NNS | denotes | patients |
| T6163 | 1637-1645 | VBN | denotes | improved |
| T27596 | 1646-1648 | IN | denotes | in |
| T10929 | 1649-1652 | DT | denotes | the |
| T87507 | 1653-1661 | JJ | denotes | clinical |
| T10805 | 1661-1662 | -COMMA- | denotes | , |
| T49266 | 1663-1673 | NN | denotes | laboratory |
| T95692 | 1673-1674 | -COMMA- | denotes | , |
| T51590 | 1675-1678 | CC | denotes | and |
| T63732 | 1679-1691 | JJ | denotes | paraclinical |
| T58895 | 1692-1700 | NNS | denotes | outcomes |
| T85504 | 1702-1709 | JJ | denotes | Passive |
| T86520 | 1710-1722 | NN | denotes | immunization |
| T22143 | 1723-1731 | VBZ | denotes | protects |
| T80547 | 1732-1739 | IN | denotes | against |
| T21735 | 1740-1747 | NN | denotes | disease |
| T15590 | 1747-1748 | -COMMA- | denotes | , |
| T4169 | 1749-1752 | CC | denotes | and |
| T50400 | 1753-1755 | IN | denotes | so |
| T4187 | 1756-1758 | PRP | denotes | it |
| T38504 | 1759-1765 | MD | denotes | should |
| T8453 | 1766-1768 | VB | denotes | be |
| T27914 | 1769-1781 | VBN | denotes | administered |
| T25991 | 1782-1784 | RB | denotes | as |
| T54707 | 1785-1790 | RB | denotes | early |
| T29802 | 1791-1793 | IN | denotes | as |
| T24869 | 1794-1802 | JJ | denotes | possible |
| T10896 | 1803-1807 | WRB | denotes | when |
| T25638 | 1808-1811 | DT | denotes | the |
| T29960 | 1812-1819 | NN | denotes | patient |
| T20464 | 1820-1822 | VBZ | denotes | is |
| T3036 | 1823-1832 | VBN | denotes | diagnosed |
| T87261 | 1834-1841 | NNS | denotes | Studies |
| T96660 | 1842-1846 | VBP | denotes | show |
| T29990 | 1847-1851 | IN | denotes | that |
| T81080 | 1852-1855 | DT | denotes | the |
| T36950 | 1856-1861 | JJ | denotes | viral |
| T53426 | 1862-1865 | NN | denotes | RNA |
| T78293 | 1866-1868 | IN | denotes | of |
| T18048 | 1869-1878 | NN | denotes | 2019-nCoV |
| T93176 | 1879-1886 | VBZ | denotes | reaches |
| T83675 | 1887-1890 | PRP-DOLLAR- | denotes | its |
| T2594 | 1891-1895 | NN | denotes | peak |
| T62926 | 1896-1902 | IN | denotes | during |
| T35185 | 1903-1906 | DT | denotes | the |
| T47524 | 1907-1912 | JJ | denotes | first |
| T79772 | 1913-1917 | NN | denotes | week |
| T85972 | 1918-1921 | CC | denotes | and |
| T60597 | 1922-1926 | RB | denotes | then |
| T18711 | 1927-1936 | RB | denotes | gradually |
| T40522 | 1937-1946 | VBZ | denotes | decreases |
| T67874 | 1947-1950 | CC | denotes | and |
| T80013 | 1951-1955 | IN | denotes | that |
| T48373 | 1956-1959 | NN | denotes | IgG |
| T85015 | 1960-1963 | CC | denotes | and |
| T48892 | 1964-1967 | NN | denotes | IgM |
| T97802 | 1968-1973 | VBP | denotes | begin |
| T54813 | 1974-1976 | TO | denotes | to |
| T87582 | 1977-1981 | VB | denotes | rise |
| T15243 | 1982-1986 | IN | denotes | from |
| T79089 | 1987-1990 | DT | denotes | the |
| T92830 | 1991-1995 | JJ | denotes | 10th |
| T91091 | 1996-1999 | NN | denotes | day |
| T75308 | 2000-2002 | IN | denotes | so |
| T98992 | 2003-2007 | IN | denotes | that |
| T91226 | 2008-2012 | JJS | denotes | most |
| T66875 | 2013-2021 | NNS | denotes | patients |
| T44373 | 2022-2026 | VBP | denotes | have |
| T45012 | 2027-2037 | JJ | denotes | anti-viral |
| T2304 | 2038-2048 | NNS | denotes | antibodies |
| T90719 | 2049-2051 | IN | denotes | by |
| T66178 | 2052-2055 | DT | denotes | the |
| T38757 | 2056-2060 | JJ | denotes | 14th |
| T73930 | 2061-2064 | NN | denotes | day |
| R83120 | T2182 | T55819 | arg1Of | immunoglobulins,4.2 |
| R86188 | T2182 | T56180 | arg1Of | immunoglobulins,Intravenous |
| R54403 | T2182 | T41175 | arg1Of | immunoglobulins,( |
| R42896 | T97867 | T41175 | arg2Of | IVIG,( |
| R53615 | T16816 | T41175 | arg3Of | ),( |
| R37061 | T95212 | T56020 | arg1Of | Hypothesis,4.2.1 |
| R21455 | T95212 | T84611 | arg1Of | Hypothesis,: |
| R41659 | T50853 | T84611 | arg2Of | contains,: |
| R26320 | T95417 | T50853 | arg1Of | IVIG,contains |
| R55634 | T83960 | T50853 | arg2Of | pool,contains |
| R11871 | T83960 | T65863 | arg1Of | pool,a |
| R81126 | T83960 | T68527 | arg1Of | pool,large |
| R87985 | T83960 | T57480 | arg1Of | pool,of |
| R85206 | T50450 | T57480 | arg2Of | antibodies,of |
| R95689 | T50450 | T98962 | arg1Of | antibodies,human |
| R7397 | T12037 | T52317 | arg1Of | IVIG,is |
| R59827 | T32201 | T52317 | arg2Of | treatment,is |
| R45922 | T32201 | T83276 | arg1Of | treatment,an |
| R32666 | T32201 | T47689 | arg1Of | treatment,immunomodulatory |
| R38821 | T32201 | T26744 | arg1Of | treatment,currently |
| R80185 | T26744 | T6595 | arg1Of | currently,useful |
| R62385 | T6595 | T61951 | arg1Of | useful,for |
| R78431 | T96672 | T61951 | arg2Of | variety,for |
| R3964 | T96672 | T78252 | arg1Of | variety,a |
| R72167 | T96672 | T75647 | arg1Of | variety,of |
| R82814 | T37666 | T75647 | arg2Of | diseases,of |
| R55274 | T37666 | T64366 | arg1Of | diseases,human |
| R31515 | T37666 | T30663 | arg1Of | diseases,that |
| R12726 | T37666 | T71611 | arg1Of | diseases,share |
| R20851 | T35011 | T71611 | arg2Of | origin,share |
| R86274 | T35011 | T4369 | arg1Of | origin,an |
| R95215 | T35011 | T95969 | arg1Of | origin,idiopathic |
| R10701 | T32201 | T94518 | arg1Of | treatment,"," |
| R19665 | T32201 | T34533 | arg1Of | treatment,ranging |
| R89530 | T34533 | T57537 | arg1Of | ranging,from |
| R77337 | T10634 | T57537 | arg2Of | disorders,from |
| R63281 | T10634 | T47481 | arg1Of | disorders,autoimmune |
| R45693 | T34533 | T96539 | arg1Of | ranging,to |
| R65268 | T91348 | T96539 | arg2Of | deficiencies,to |
| R94792 | T91348 | T18270 | arg1Of | deficiencies,primary |
| R91107 | T91348 | T92790 | arg1Of | deficiencies,antibody |
| R9941 | T10629 | T23275 | arg1Of | shown,Also |
| R28227 | T10629 | T97483 | arg1Of | shown,"," |
| R92669 | T12179 | T44219 | arg1Of | IVIG,has |
| R31307 | T10629 | T44219 | arg2Of | shown,has |
| R77637 | T12179 | T10629 | arg1Of | IVIG,shown |
| R23512 | T67208 | T10629 | arg2Of | results,shown |
| R8504 | T67208 | T45168 | arg1Of | results,promising |
| R20697 | T67208 | T77083 | arg1Of | results,in |
| R78894 | T72909 | T77083 | arg2Of | case,in |
| R82064 | T72909 | T84121 | arg1Of | case,of |
| R98709 | T6178 | T84121 | arg2Of | and,of |
| R28624 | T52785 | T92712 | arg1Of | and,severe |
| R80380 | T52785 | T79863 | arg2Of | and,( |
| R24626 | T80386 | T79863 | arg3Of | ),( |
| R19944 | T43956 | T66824 | arg1Of | as,such |
| R49580 | T52785 | T43956 | arg1Of | and,as |
| R37840 | T13628 | T43956 | arg2Of | ",",as |
| R28995 | T9832 | T13628 | arg1Of | sepsis,"," |
| R16863 | T14835 | T13628 | arg2Of | infection,"," |
| R40263 | T14835 | T62406 | arg1Of | infection,Parvovirus |
| R95673 | T14835 | T99835 | arg1Of | infection,B19 |
| R52070 | T13628 | T15497 | arg1Of | ",","," |
| R13275 | T62294 | T15497 | arg2Of | encephalitis,"," |
| R22619 | T76795 | T90831 | arg1Of | Nile,West |
| R23224 | T62294 | T76795 | arg1Of | encephalitis,Nile |
| R99263 | T62294 | T72325 | arg1Of | encephalitis,virus |
| R15788 | T62294 | T79163 | arg1Of | encephalitis,"," |
| R54321 | T42313 | T79163 | arg2Of | HIV,"," |
| R99309 | T52785 | T73958 | arg1Of | and,"," |
| R85642 | T8038 | T29310 | arg1Of | infections,Clostridium |
| R55554 | T8038 | T49447 | arg1Of | infections,difficile |
| R94197 | T8038 | T10219 | arg1Of | infections,"," |
| R30216 | T55185 | T10219 | arg2Of | avium,"," |
| R46944 | T55185 | T3443 | arg1Of | avium,Mycobacterium |
| R36023 | T10219 | T2677 | arg1Of | ",","," |
| R30475 | T65630 | T2677 | arg2Of | tuberculosis,"," |
| R32473 | T65630 | T67405 | arg1Of | tuberculosis,Mycobacterium |
| R79700 | T52785 | T60726 | arg1Of | and,"," |
| R5424 | T2677 | T52785 | arg1Of | ",",and |
| R82963 | T90848 | T52785 | arg2Of | infections,and |
| R12367 | T90848 | T44446 | arg1Of | infections,Nocardia |
| R36176 | T52785 | T6178 | arg1Of | and,and |
| R5432 | T17705 | T6178 | arg2Of | infections,and |
| R7624 | T17705 | T68317 | arg1Of | infections,recurrent |
| R48790 | T6178 | T68999 | arg1Of | and,in |
| R33893 | T62247 | T68999 | arg2Of | deficiencies,in |
| R41252 | T62247 | T18422 | arg1Of | deficiencies,primary |
| R34450 | T62247 | T52471 | arg1Of | deficiencies,antibodies |
| R24969 | T62247 | T55724 | arg1Of | deficiencies,[ |
| R29860 | T27007 | T55724 | arg2Of | 21,[ |
| R45347 | T97422 | T55724 | arg3Of | ],[ |
| R18045 | T48684 | T8813 | arg1Of | patients,Most |
| R91845 | T48684 | T37814 | arg1Of | patients,develop |
| R13100 | T41895 | T37814 | arg2Of | antibodies,develop |
| R35710 | T37814 | T32237 | arg1Of | develop,against |
| R20807 | T51386 | T32237 | arg2Of | and,against |
| R6800 | T51386 | T55833 | arg1Of | and,the |
| R22109 | T23466 | T51386 | arg1Of | NP,and |
| R81797 | T97267 | T51386 | arg2Of | RBD,and |
| R91140 | T51386 | T48238 | arg1Of | and,of |
| R87740 | T17626 | T48238 | arg2Of | 2019-nCoV,of |
| R8876 | T37814 | T87676 | arg1Of | develop,during |
| R35461 | T36179 | T87676 | arg2Of | week,during |
| R97441 | T36179 | T56543 | arg1Of | week,the |
| R2585 | T36179 | T74019 | arg1Of | week,second |
| R34363 | T37814 | T61939 | arg1Of | develop,after |
| R46687 | T47949 | T61939 | arg2Of | onset,after |
| R33556 | T47949 | T53819 | arg1Of | onset,infection |
| R6993 | T37814 | T10621 | arg1Of | develop,[ |
| R3294 | T31327 | T10621 | arg2Of | 22,[ |
| R78306 | T53799 | T10621 | arg3Of | ],[ |
| R98284 | T76985 | T6758 | arg1Of | Analysis,of |
| R72949 | T73739 | T6758 | arg2Of | samples,of |
| R94093 | T73739 | T88720 | arg1Of | samples,serum |
| R64474 | T76985 | T20072 | arg1Of | Analysis,collected |
| R79737 | T64515 | T20072 | arg2Of | days,collected |
| R31087 | T64515 | T30704 | arg1Of | days,14 |
| R58487 | T30704 | T66398 | arg1Of | 14,or |
| R48701 | T30704 | T43796 | arg1Of | 14,more |
| R91116 | T20072 | T88119 | arg1Of | collected,after |
| R29180 | T69102 | T88119 | arg2Of | revealed,after |
| R61094 | T78997 | T33297 | arg1Of | onset,symptom |
| R30751 | T78997 | T69102 | arg1Of | onset,revealed |
| R85646 | T51393 | T69102 | arg2Of | detection,revealed |
| R94930 | T51393 | T49412 | arg1Of | detection,of |
| R15007 | T84785 | T49412 | arg2Of | antibodies,of |
| R35220 | T84785 | T86080 | arg1Of | antibodies,IgG |
| R17029 | T86080 | T42365 | arg1Of | IgG,and |
| R36223 | T24248 | T42365 | arg2Of | IgM,and |
| R4871 | T84785 | T24248 | arg1Of | antibodies,IgM |
| R37373 | T51393 | T33598 | arg1Of | detection,against |
| R80609 | T65176 | T33598 | arg2Of | NP,against |
| R29116 | T51393 | T29543 | arg1Of | detection,in |
| R74727 | T54079 | T29543 | arg2Of | and,in |
| R31620 | T4274 | T67075 | arg1Of | %,94 |
| R41074 | T71868 | T4274 | arg1Of | %,% |
| R32415 | T4274 | T73088 | arg1Of | %,and |
| R53047 | T74097 | T73088 | arg2Of | 88,and |
| R60224 | T71868 | T74097 | arg1Of | %,88 |
| R30825 | T71868 | T54079 | arg1Of | %,and |
| R92508 | T73098 | T54079 | arg2Of | RBD,and |
| R99739 | T54079 | T69539 | arg1Of | and,in |
| R9744 | T64615 | T69539 | arg2Of | %,in |
| R73124 | T78691 | T87988 | arg1Of | %,100 |
| R67370 | T64615 | T78691 | arg1Of | %,% |
| R15728 | T78691 | T18580 | arg1Of | %,and |
| R74845 | T46489 | T18580 | arg2Of | 94,and |
| R42305 | T64615 | T46489 | arg1Of | %,94 |
| R38001 | T51393 | T60810 | arg1Of | detection,among |
| R89986 | T38563 | T60810 | arg2Of | patients,among |
| R54593 | T38563 | T93829 | arg1Of | patients,with |
| R6445 | T24980 | T93829 | arg2Of | COVID19,with |
| R86911 | T54246 | T44838 | arg1Of | show,consistently |
| R41127 | T89545 | T54246 | arg1Of | Studies,show |
| R52555 | T7060 | T54246 | arg2Of | accompany,show |
| R1890 | T7060 | T20581 | arg1Of | accompany,that |
| R15150 | T48431 | T54967 | arg2Of | levels,increased |
| R79272 | T48431 | T27422 | arg1Of | levels,immunoglobulin |
| R9994 | T48431 | T7060 | arg1Of | levels,accompany |
| R27595 | T24866 | T7060 | arg2Of | transition,accompany |
| R10059 | T24866 | T92743 | arg1Of | transition,the |
| R64970 | T24866 | T9522 | arg1Of | transition,from |
| R11593 | T25388 | T9522 | arg2Of | course,from |
| R11280 | T7048 | T69120 | arg1Of | late,early |
| R61089 | T7048 | T81312 | arg1Of | late,to |
| R36970 | T25388 | T7048 | arg1Of | course,late |
| R76248 | T25388 | T44741 | arg1Of | course,of |
| R16578 | T20679 | T44741 | arg2Of | COVID19,of |
| R93295 | T6735 | T32751 | arg1Of | It,poses |
| R68469 | T21434 | T32751 | arg2Of | possibility,poses |
| R17888 | T21434 | T41840 | arg1Of | possibility,the |
| R71902 | T91321 | T21434 | arg2Of | help,possibility |
| R4510 | T91321 | T75450 | arg1Of | help,that |
| R34056 | T48129 | T55251 | arg1Of | therapy,IVIG |
| R30440 | T48129 | T90120 | arg1Of | therapy,might |
| R46659 | T91321 | T90120 | arg2Of | help,might |
| R94505 | T48129 | T91321 | arg1Of | therapy,help |
| R59227 | T64443 | T91321 | arg2Of | accelerate,help |
| R39248 | T64443 | T89890 | arg1Of | accelerate,to |
| R27615 | T48129 | T64443 | arg1Of | therapy,accelerate |
| R41612 | T5150 | T64443 | arg2Of | recovery,accelerate |
| R13579 | T5150 | T43666 | arg1Of | recovery,from |
| R80924 | T85289 | T43666 | arg2Of | COVID-19,from |
| R82140 | T31699 | T72940 | arg1Of | Rationale,4.2.2 |
| R99597 | T31699 | T6254 | arg1Of | Rationale,: |
| R25082 | T22631 | T6254 | arg2Of | help,: |
| R45006 | T80516 | T69063 | arg1Of | IVIG,might |
| R51148 | T22631 | T69063 | arg2Of | help,might |
| R70932 | T80516 | T22631 | arg1Of | IVIG,help |
| R90242 | T98862 | T22631 | arg2Of | improve,help |
| R33852 | T98862 | T88012 | arg1Of | improve,to |
| R33240 | T80516 | T98862 | arg1Of | IVIG,improve |
| R77199 | T20348 | T98862 | arg2Of | outcome,improve |
| R11936 | T20348 | T98671 | arg1Of | outcome,the |
| R19763 | T20348 | T65200 | arg1Of | outcome,of |
| R2046 | T90061 | T65200 | arg2Of | patients,of |
| R70326 | T90061 | T66297 | arg1Of | patients,with |
| R67204 | T53417 | T66297 | arg2Of | COVID-19,with |
| R50369 | T21718 | T18993 | arg1Of | study,The |
| R14407 | T21718 | T64168 | arg1Of | study,[ |
| R76274 | T66430 | T64168 | arg2Of | 23,[ |
| R38202 | T95152 | T64168 | arg3Of | ],[ |
| R86526 | T21718 | T31198 | arg1Of | study,included |
| R31769 | T65830 | T31198 | arg2Of | patients,included |
| R46612 | T65830 | T55004 | arg1Of | patients,ten |
| R25333 | T65830 | T56952 | arg1Of | patients,with |
| R9661 | T98815 | T56952 | arg2Of | COVID-19,with |
| R66734 | T98815 | T69048 | arg1Of | COVID-19,who |
| R31347 | T98815 | T75376 | arg1Of | COVID-19,demonstrated |
| R59919 | T24326 | T75376 | arg2Of | symptoms,demonstrated |
| R40351 | T24326 | T59786 | arg1Of | symptoms,worsening |
| R92905 | T31198 | T13700 | arg1Of | included,"," |
| R16771 | T13833 | T13700 | arg2Of | and,"," |
| R26629 | T13833 | T79561 | arg1Of | and,e.g. |
| R4076 | T13833 | T83448 | arg1Of | and,"," |
| R17219 | T21718 | T77014 | arg1Of | study,decreased |
| R22057 | T31095 | T77014 | arg2Of | count,decreased |
| R79029 | T31095 | T40148 | arg1Of | count,lymphocyte |
| R1770 | T77014 | T13833 | arg1Of | decreased,and |
| R37459 | T80531 | T13833 | arg2Of | decreased,and |
| R47262 | T21718 | T80531 | arg1Of | study,decreased |
| R34129 | T11859 | T80531 | arg2Of | and,decreased |
| R19341 | T3471 | T26060 | arg1Of | ratio,PaO2/FIO2 |
| R92577 | T3471 | T11859 | arg1Of | ratio,and |
| R40508 | T65980 | T11859 | arg2Of | saturation,and |
| R18986 | T65980 | T6067 | arg1Of | saturation,oxygen |
| R39324 | T13833 | T58632 | arg1Of | and,"," |
| R49635 | T13833 | T52543 | arg1Of | and,following |
| R4003 | T6426 | T52543 | arg2Of | plus,following |
| R22662 | T84435 | T44273 | arg1Of | treatment,with |
| R78212 | T25963 | T44273 | arg2Of | corticosteroid,with |
| R70976 | T25963 | T99668 | arg1Of | corticosteroid,a |
| R50003 | T25963 | T65524 | arg1Of | corticosteroid,short-term |
| R2970 | T25963 | T66169 | arg1Of | corticosteroid,moderate-dose |
| R89182 | T25963 | T54040 | arg1Of | corticosteroid,( |
| R82941 | T75851 | T54040 | arg2Of | 80 mg/d,( |
| R99800 | T55858 | T54040 | arg3Of | ),( |
| R95496 | T75851 | T15835 | arg1Of | 80 mg/d,methylprednisolone |
| R36752 | T84435 | T6426 | arg1Of | treatment,plus |
| R79540 | T60445 | T6426 | arg2Of | immunoglobulin,plus |
| R41260 | T60445 | T91733 | arg1Of | immunoglobulin,( |
| R75502 | T10263 | T91733 | arg2Of | 10 g/d,( |
| R50386 | T89099 | T91733 | arg3Of | ),( |
| R26413 | T6163 | T32422 | arg1Of | improved,After |
| R62745 | T38661 | T32422 | arg2Of | switching,After |
| R35046 | T64285 | T38661 | arg1Of | all,switching |
| R97543 | T38661 | T47400 | arg1Of | switching,to |
| R45642 | T22917 | T47400 | arg2Of | dose,to |
| R79576 | T22917 | T27854 | arg1Of | dose,the |
| R56085 | T22917 | T88178 | arg1Of | dose,double |
| R64025 | T22917 | T27562 | arg1Of | dose,of |
| R36622 | T91618 | T27562 | arg2Of | plus,of |
| R47040 | T26688 | T69861 | arg1Of | methylprednisolone,1600 mg/d |
| R96957 | T26688 | T91618 | arg1Of | methylprednisolone,plus |
| R59825 | T82872 | T91618 | arg2Of | immunoglobulin,plus |
| R2563 | T82872 | T63033 | arg1Of | immunoglobulin,20 g/d |
| R17542 | T6163 | T48110 | arg1Of | improved,"," |
| R33163 | T64285 | T67888 | arg1Of | all,of |
| R47106 | T67776 | T67888 | arg2Of | patients,of |
| R68832 | T67776 | T16788 | arg1Of | patients,the |
| R41521 | T64285 | T6163 | arg1Of | all,improved |
| R92060 | T6163 | T27596 | arg1Of | improved,in |
| R79224 | T58895 | T27596 | arg2Of | outcomes,in |
| R14909 | T58895 | T10929 | arg1Of | outcomes,the |
| R43963 | T58895 | T87507 | arg1Of | outcomes,clinical |
| R46705 | T87507 | T10805 | arg1Of | clinical,"," |
| R31644 | T49266 | T10805 | arg2Of | laboratory,"," |
| R53992 | T58895 | T49266 | arg1Of | outcomes,laboratory |
| R52803 | T51590 | T95692 | arg1Of | and,"," |
| R16749 | T10805 | T51590 | arg1Of | ",",and |
| R63324 | T63732 | T51590 | arg2Of | paraclinical,and |
| R41915 | T58895 | T63732 | arg1Of | outcomes,paraclinical |
| R55232 | T86520 | T85504 | arg1Of | immunization,Passive |
| R10991 | T86520 | T22143 | arg1Of | immunization,protects |
| R69581 | T22143 | T80547 | arg1Of | protects,against |
| R58848 | T21735 | T80547 | arg2Of | disease,against |
| R89140 | T4169 | T15590 | arg1Of | and,"," |
| R87834 | T22143 | T4169 | arg1Of | protects,and |
| R91588 | T27914 | T4169 | arg2Of | administered,and |
| R50799 | T27914 | T50400 | arg1Of | administered,so |
| R82498 | T4187 | T38504 | arg1Of | it,should |
| R94705 | T27914 | T38504 | arg2Of | administered,should |
| R14592 | T4187 | T8453 | arg1Of | it,be |
| R28181 | T27914 | T8453 | arg2Of | administered,be |
| R94232 | T4187 | T27914 | arg2Of | it,administered |
| R68805 | T54707 | T25991 | arg1Of | early,as |
| R98402 | T27914 | T54707 | arg1Of | administered,early |
| R46464 | T54707 | T29802 | arg1Of | early,as |
| R22163 | T24869 | T29802 | arg2Of | possible,as |
| R45063 | T27914 | T10896 | arg1Of | administered,when |
| R89732 | T3036 | T10896 | arg2Of | diagnosed,when |
| R29783 | T29960 | T25638 | arg1Of | patient,the |
| R50945 | T29960 | T20464 | arg1Of | patient,is |
| R9347 | T3036 | T20464 | arg2Of | diagnosed,is |
| R96008 | T29960 | T3036 | arg2Of | patient,diagnosed |
| R15494 | T87261 | T96660 | arg1Of | Studies,show |
| R35568 | T67874 | T96660 | arg2Of | and,show |
| R23868 | T85972 | T29990 | arg1Of | and,that |
| R73123 | T53426 | T81080 | arg1Of | RNA,the |
| R53013 | T53426 | T36950 | arg1Of | RNA,viral |
| R7573 | T53426 | T78293 | arg1Of | RNA,of |
| R81045 | T18048 | T78293 | arg2Of | 2019-nCoV,of |
| R2548 | T53426 | T93176 | arg1Of | RNA,reaches |
| R70781 | T2594 | T93176 | arg2Of | peak,reaches |
| R53482 | T2594 | T83675 | arg1Of | peak,its |
| R57386 | T93176 | T62926 | arg1Of | reaches,during |
| R56679 | T79772 | T62926 | arg2Of | week,during |
| R40741 | T79772 | T35185 | arg1Of | week,the |
| R25803 | T79772 | T47524 | arg1Of | week,first |
| R42816 | T93176 | T85972 | arg1Of | reaches,and |
| R99315 | T40522 | T85972 | arg2Of | decreases,and |
| R84704 | T40522 | T60597 | arg1Of | decreases,then |
| R48610 | T40522 | T18711 | arg1Of | decreases,gradually |
| R43001 | T53426 | T40522 | arg1Of | RNA,decreases |
| R36109 | T85972 | T67874 | arg1Of | and,and |
| R96845 | T80013 | T67874 | arg2Of | that,and |
| R2631 | T97802 | T80013 | arg2Of | begin,that |
| R52755 | T48373 | T85015 | arg1Of | IgG,and |
| R60239 | T48892 | T85015 | arg2Of | IgM,and |
| R48496 | T85015 | T97802 | arg1Of | and,begin |
| R27628 | T87582 | T97802 | arg2Of | rise,begin |
| R58171 | T87582 | T54813 | arg1Of | rise,to |
| R42427 | T85015 | T87582 | arg1Of | and,rise |
| R47112 | T87582 | T15243 | arg1Of | rise,from |
| R54860 | T91091 | T15243 | arg2Of | day,from |
| R40258 | T91091 | T79089 | arg1Of | day,the |
| R81041 | T91091 | T92830 | arg1Of | day,10th |
| R10340 | T87582 | T75308 | arg1Of | rise,so |
| R28808 | T44373 | T75308 | arg2Of | have,so |
| R89374 | T75308 | T98992 | arg1Of | so,that |
| R10355 | T66875 | T91226 | arg1Of | patients,most |
| R53372 | T66875 | T44373 | arg1Of | patients,have |
| R13811 | T2304 | T44373 | arg2Of | antibodies,have |
| R80044 | T2304 | T45012 | arg1Of | antibodies,anti-viral |
| R71283 | T44373 | T90719 | arg1Of | have,by |
| R16551 | T73930 | T90719 | arg2Of | day,by |
| R27976 | T73930 | T66178 | arg1Of | day,the |
| R35060 | T73930 | T38757 | arg1Of | day,14th |
LitCovid-sample-PD-FMA
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T134 | 17-32 | Body_part | denotes | immunoglobulins | http://purl.org/sig/ont/fma/fma62871 |
| T135 | 272-280 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
| T136 | 425-428 | Body_part | denotes | HIV | http://purl.org/sig/ont/fma/fma278683 |
| T137 | 736-741 | Body_part | denotes | serum | http://purl.org/sig/ont/fma/fma63083 |
| T138 | 818-821 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
| T139 | 826-829 | Body_part | denotes | IgM | http://purl.org/sig/ont/fma/fma62873 |
| T140 | 961-975 | Body_part | denotes | immunoglobulin | http://purl.org/sig/ont/fma/fma62871 |
| T141 | 1326-1336 | Body_part | denotes | lymphocyte | http://purl.org/sig/ont/fma/fma62863 |
| T142 | 1497-1511 | Body_part | denotes | immunoglobulin | http://purl.org/sig/ont/fma/fma62871 |
| T143 | 1601-1615 | Body_part | denotes | immunoglobulin | http://purl.org/sig/ont/fma/fma62871 |
| T144 | 1862-1865 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
| T145 | 1956-1959 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
| T146 | 1964-1967 | Body_part | denotes | IgM | http://purl.org/sig/ont/fma/fma62873 |
LitCovid-sample-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T119 | 240-260 | Disease | denotes | autoimmune disorders | http://purl.obolibrary.org/obo/MONDO_0007179 |
| T120 | 264-293 | Disease | denotes | primary antibody deficiencies | http://purl.obolibrary.org/obo/MONDO_0015517 |
| T121 | 384-393 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T122 | 405-423 | Disease | denotes | virus encephalitis | http://purl.obolibrary.org/obo/MONDO_0006009 |
| T123 | 430-462 | Disease | denotes | Clostridium difficile infections | http://purl.obolibrary.org/obo/MONDO_0000705 |
| T124 | 499-511 | Disease | denotes | tuberculosis | http://purl.obolibrary.org/obo/MONDO_0018076 |
| T125 | 517-536 | Disease | denotes | Nocardia infections | http://purl.obolibrary.org/obo/MONDO_0017776 |
| T126 | 552-565 | Disease | denotes | infections in | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T127 | 566-597 | Disease | denotes | primary antibodies deficiencies | http://purl.obolibrary.org/obo/MONDO_0015517 |
| T128 | 702-711 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T129 | 911-918 | Disease | denotes | COVID19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T130 | 1037-1044 | Disease | denotes | COVID19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T131 | 1128-1136 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T132 | 1213-1221 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T133 | 1264-1272 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-sample-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T4 | 240-260 | Phenotype | denotes | autoimmune disorders | http://purl.obolibrary.org/obo/HP_0002960 |
| T5 | 361-367 | Phenotype | denotes | sepsis | http://purl.obolibrary.org/obo/HP_0100806 |
| T6 | 411-423 | Phenotype | denotes | encephalitis | http://purl.obolibrary.org/obo/HP_0002383 |
| T7 | 542-562 | Phenotype | denotes | recurrent infections | http://purl.obolibrary.org/obo/HP_0002719 |
| T8 | 951-982 | Phenotype | denotes | increased immunoglobulin levels | http://purl.obolibrary.org/obo/HP_0010702 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T141 | 0-39 | Sentence | denotes | 4.2 Intravenous immunoglobulins (IVIG) |
| T142 | 41-106 | Sentence | denotes | 4.2.1 Hypothesis: IVIG contains a large pool of human antibodies |
| T143 | 107-294 | Sentence | denotes | IVIG is an immunomodulatory treatment currently useful for a variety of human diseases that share an idiopathic origin, ranging from autoimmune disorders to primary antibody deficiencies. |
| T144 | 295-603 | Sentence | denotes | Also, IVIG has shown promising results in case of severe (such as sepsis, Parvovirus B19 infection, West Nile virus encephalitis, HIV, Clostridium difficile infections, Mycobacterium avium, Mycobacterium tuberculosis, and Nocardia infections) and recurrent infections in primary antibodies deficiencies [21]. |
| T145 | 604-723 | Sentence | denotes | Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22]. |
| T146 | 724-919 | Sentence | denotes | Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19. |
| T147 | 920-1045 | Sentence | denotes | Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19. |
| T148 | 1046-1137 | Sentence | denotes | It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19. |
| T149 | 1139-1221 | Sentence | denotes | 4.2.2 Rationale: IVIG might help to improve the outcome of patients with COVID-19 |
| T150 | 1222-1521 | Sentence | denotes | The study [23] included ten patients with COVID-19 who demonstrated worsening symptoms, e.g., decreased lymphocyte count and decreased PaO2/FIO2 ratio and oxygen saturation, following treatment with a short-term moderate-dose corticosteroid (methylprednisolone 80 mg/d) plus immunoglobulin (10 g/d). |
| T151 | 1522-1701 | Sentence | denotes | After switching to the double dose of 1600 mg/d methylprednisolone plus 20 g/d immunoglobulin, all of the patients improved in the clinical, laboratory, and paraclinical outcomes. |
| T152 | 1702-1833 | Sentence | denotes | Passive immunization protects against disease, and so it should be administered as early as possible when the patient is diagnosed. |
| T153 | 1834-2065 | Sentence | denotes | Studies show that the viral RNA of 2019-nCoV reaches its peak during the first week and then gradually decreases and that IgG and IgM begin to rise from the 10th day so that most patients have anti-viral antibodies by the 14th day. |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T4 | 240-260 | Phenotype | denotes | autoimmune disorders | http://purl.obolibrary.org/obo/HP_0002960 |
| T5 | 361-367 | Phenotype | denotes | sepsis | http://purl.obolibrary.org/obo/HP_0100806 |
| T6 | 411-423 | Phenotype | denotes | encephalitis | http://purl.obolibrary.org/obo/HP_0002383 |
| T7 | 542-562 | Phenotype | denotes | recurrent infections | http://purl.obolibrary.org/obo/HP_0002719 |
| T8 | 951-982 | Phenotype | denotes | increased immunoglobulin levels | http://purl.obolibrary.org/obo/HP_0010702 |